enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Transitional Cell
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Trial Timeline
Oct 11, 2017 → Sep 11, 2026
NCT ID
NCT03288545About enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine is a phase 1/2 stage product being developed by Astellas Pharma for Carcinoma, Transitional Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03288545. Target conditions include Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Transitional Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03288545 | Phase 1/2 | Active |
Competing Products
20 competing products in Carcinoma, Transitional Cell